Pioneering pharmaceutical excellence

CARBOGEN AMCIS is a leading global contract development and manufacturing organisation (CDMO), trusted by pharmaceutical and biopharmaceutical companies worldwide. With over 40 years of expertise, the company offers an integrated suite of services across drug substance and drug product development, helping clients to bring life-changing therapies to market with precision and efficiency.

Global presence, local expertise

As part of the Indian Dishman CARBOGEN AMCIS Group, the company operates eight state-of-the-art facilities across Switzerland, France, the UK, the Netherlands and China, supported by a team of over 1,100 professionals. This global reach ensures localised support while maintaining consistent quality and regulatory compliance. CARBOGEN AMCIS’ geographic footprint, with locations in multiple countries, enhances our ability to provide a broad perspective and maintain commitment through independent locations around the world. This international presence enhances our understanding of regional risks and regulatory environments. As a result, we can provide more resilient and adaptable drug substance supply chain solutions. The facilities meet the highest international standards, with successful inspections from authorities including the US Food and Drug Adminstration (FDA), Swissmedic, ANVISA, and Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM).

Our vision

We bring science to life by providing innovative solutions in products and services, contributing to the well-being of people and the planet.

Core capabilities

Our capabilities include contract chemical process R&D, the supply of active pharmaceutical ingredients (APIs), drug products for preclinical studies, clinical trials and commercial use, and high-quality cholesterol and vitamin D analogue products.

“CARBOGEN AMCIS is full of people passionate about process chemistry, inter-project collaboration is actively encouraged and the availability of highly skilled people to help problem solve is very reassuring. There is continued investment in facilities and resources to offer the best service to customers.” – Magdalena Skop, technical specialist analytics